Joseph Triggs, MD, PhD retweeted
📢‼️ Calling #GITwitter applying for Advanced Endo Fellowship ‼️
@FoxChaseCancer in Philadelphia now offers a 4th yr Interventional Endo Fellowship
Learn/train with THE 💪trifecta: David Loren, Joe Triggs and Me!
@ASGEendoscopy @AmerGastroAssn
foxchase.org/research-traini…
Great weekend. Thanks for having me @NM_IntEndo!! Lots of fun to see so many friends, hear so many great lectures and watch so many great cases.
Proud of our @NM_IntEndo team to make #chicagolive a successful course. Appreciate all the guest faculty coming to @NMGastro and everyone working together behind the scenes to make it all happen
Joseph Triggs, MD, PhD retweeted
Calling all fellows! Join us for an immersion into endoscopy in Chicago, Oct 26. Full grants to cover air and hotel still available. You will meet like minded trainees and network with the GI Legends. Still time. Sign up now! @LiverFellow @TrieuMD @AustinChiangMD @ASGEendoscopy
The fellows course lectures at #ChicagoLive might be the most entertaining yet educational in 2023.
Travel scholarships are available for fellows to attend. Sign up today!
northwestern.cloud-cme.com/c…
Joseph Triggs, MD, PhD retweeted
When your Chief, David Loren @d21loren, gets to be on TV for the Phillies game.. the interventional GI team (@JRTriggs) all rally to support him and @FoxChaseCancer !
#strikeoutcancer
#phillies
Persistent reflux is a problem. Can we tell who is going to RECUR?? @Scopesdoc
#EditorsChoice "Novel histologic score predicts recurrent intestinal metaplasia after successful
endoscopic eradication therapy" from @JRTriggs and colleagues, this month in @DOTEsophagus
ow.ly/oXk750OnvMr
Joseph Triggs, MD, PhD retweeted
#EditorsChoice "Novel histologic score predicts recurrent intestinal metaplasia after successful
endoscopic eradication therapy" from @JRTriggs and colleagues, this month in @DOTEsophagus
ow.ly/oXk750OnvMr
Great course and lots of fun! Thank you @ASGEendoscopy and course directors @MonicaSaumoyMD and David Loren for the opportunity to teach and learn with this crew.
It was so great spending a weekend and hanging out with these lovely people at the @ASGEendoscopy STAR suturing course! #bluebutton @drKumarGI @SighPichamol @gastrowala @JRTriggs @DennisYangMD @MonicaSaumoyMD
Miss you guys. Great seeing you both!!
Enjoyed catching up with @MonicaSaumoyMD @JRTriggs last night
Great day at the AGA Tech Summit! Thanks to @Scopesdoc and @drsethinyc for the invitation and wonderful leadership.
Amazing panel representing all stakeholders focused on Innovation in Endoscopy. 2023 AGA Tech Summit. @AmerGastroAssn @ASGEendoscopy @AmCollegeGastro
I find it depends on which provider sees the patient first. GIs typically move to scope and primary care or other providers often get esophagram.
Replying to @BilalMohammadMD @aileenbui @ScopingSundays @BenClement_MD @AhmadBazarbashi @SanchezLunaMD @vaibhav_manu @rmulkimd @DrMalSimons @LizzieAbyMD @NnekaUfereMD @AdvaniRashmiMD @AfrinKamalMD @EsophagusDoc @RishiNaikMD @JoshuaASloanDO1 @AllonKahn @KristleLynchMD
I recall this always being a debate which test to get first EGD or barium esophagram. I think the reality is EGD tends to get done first. Anyone have a different perspective?
Joseph Triggs, MD, PhD retweeted
Could not agree more. The AGA Tech Summit is a hidden gem and one that every GI would find engaging and extremely valuable for practice. Join us for this amazing event in SF!@ASGEendoscopy @AmCollegeGastro @AmerGastroAssn
For anyone interested in #innovation - this is one of the absolute BEST conferences of the year!
#TechSummit2023
Registration is now open! gastro.org/agatech
@AmerGastroAssn @drsethinyc @Scopesdoc @alisonkimphd @SherriGScott
Joseph Triggs, MD, PhD retweeted
Monday, Jan. 9, is the last day to save up to $425 on registration for the #AGATech Summit, taking place March 9-10 in San Francisco. Plus, don't forget to apply to pitch your innovation at the AGA Shark Tank competition by Feb. 6! ow.ly/1QHr50LXMUo @Scopesdoc @drsethinyc
Joseph Triggs, MD, PhD retweeted
#Penn Swallowing Conference debate of the night: How do you manage dysphagia patients with EGJOO on chronic opiates who have abnormal FLIP or TBE?
14%POEM or LHM
11%PD
60%Medical management
14%Other (see comment!)
105 votes • Final results14th ANNUAL PENN LIVE: GI ENDOSCOPY AND LIVER DISEASE 2022 - Penn Medicine - Continuing Education (CE) - 14th ANNUAL PENN LIVE: GI ENDOSCOPY AND LIVER DISEASE 2022 — join us today!! upenn.cloud-cme.com/course/c…
Joseph Triggs, MD, PhD retweeted
‼️ Due to the rapid rise of the Delta variant in our region, the @PennMedicine is now requiring pre-procedure #COVID testing for endoscopies &physiology testing ‼️
pennmedicine.org/coronavirus…
@serperm @ShaziaMSiddique @DrsMeena @penngihep @fr_hossain @FITWITMD @JRTriggs
Joseph Triggs, MD, PhD retweeted
Management of Ampullary Tumors is one of the more challenging pathologies for Endoscopists!
Join us tomorrow for the upcoming #ScopingSundays session to learn some pearls & share your tips & tricks!
Moderated by @KeneChudyMD & @bilalasifMD - & our Expert Guest @MonicaSaumoyMD!
Joseph Triggs, MD, PhD retweeted
How to Get your #COVID #Vaccine @PennMedicine ?
1✅Call to schedule an appt: 267-758-4902 (M-F 8a-5p)
2✅Same-Day Walk-ins: pennmedicine.org for sites/hours
3✅ Homebound Patients: Ask your provider to place an order!
pennmedicine.org/coronavirus…
Joseph Triggs, MD, PhD retweeted
A #tweetorial on proton pump inhibitors (PPIs)
Just for fun, which drug class is archetypal of a gastroenterologist? 😉
1/
10%5-aminosalicylic acid
10%Laxatives/anti-diarrheals
77%Proton pump inhibitors
3%Others (please specify)
1,484 votes • Final results Joseph Triggs, MD, PhD retweeted
Learn about “Blown-out myotomy: an adverse event of laparoscopic Heller myotomy and peroral endoscopic myotomy for achalasia” in this article by Triggs et al. giejournal.org/article/S0016…
@JRTriggs @JPandolfinoMD
nejm.org/doi/full/10.1056/NE… A step forward for personalized medicine and our esophageal cancer patients.
New York Times: Alternative title:
“A ‘game changer’ for pts w PDL1+ esophageal cancer, TRIPLES disease free survival. Unfortunately not effective in biomarker low-neg tumors- more work to do. A testament towards personalized medicine.”@OncoAlert nytimes.com/2021/03/31/healt…































